Anamorelin Dosing & Reconstitution Guide

Anamorelin is administered orally, with a recommended frequency of once daily. The dose range observed in clinical trials varies from 50 mg to 150 mg daily, with specific trial doses of 50 mg and 100 mg being prominently studied. In Japan, Anamorelin has received approval at a standard dose of 100 mg. The duration of treatment in clinical settings has been documented to span 12 to 24 weeks, reflecting the length of various trial protocols. For optimal absorption, it is suggested that Anamorelin be taken before breakfast on an empty stomach, although this timing is based on study conditions and may not extend to all research applications.

The pharmacokinetic profile of Anamorelin reveals an onset of effect for appetite stimulation occurring within 1 to 2 weeks of administration. The half-life of Anamorelin is reported to be between 7 to 12 hours, indicating a relatively moderate retention in the system. Notably, clinical trials have demonstrated that measurable changes in lean mass may take approximately 12 weeks to manifest, suggesting a delayed response that researchers should consider when designing studies that assess the compound's efficacy.

The safety profile of Anamorelin has been evaluated in Phase III trials, such as the ROMANA studies, which reported discontinuation rates comparable to those of placebo groups. However, some participants exhibited GH-mediated elevations in blood glucose levels, with a small percentage experiencing diabetes mellitus or glucose intolerance. Additionally, transient elevations in liver enzymes (AST and ALT) were observed, though these instances were typically mild and reversible. Contraindications for Anamorelin include the presence of QTc prolongation or other risk factors for cardiac arrhythmias, uncontrolled diabetes mellitus due to the counter-regulatory effects of growth hormone on glucose, and severe hepatic impairment, highlighting the need for careful consideration in study design.